ProCE Banner Activity

Applying HER2 Testing Results to Treatment Decisions for Patients With Solid Tumors


Download this slideset for expert perspectives and key data on HER2-targeted therapy for specific patients with advanced breast, gastroesophageal, colorectal, and lung cancers, as well as a discussion of emerging strategies for HER-altered solid tumors.

Released: March 25, 2024

Expiration: March 24, 2025



Todd M. Bauer

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Katherine M. Bever

Katherine M. Bever, MD

Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Tanya Gupta

Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

Funda Meric-Bernstam

Funda Meric-Bernstam, MD

Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
Professor, Divisions of Cancer Medicine and Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Jazz Pharmaceuticals, and Seagen.


Daiichi Sankyo, Inc.

Jazz Pharmaceuticals